Thursday, March 30, 2023 | Back issues
Courthouse News Service Courthouse News Service


MINNEAPOLIS - Shareholders claim in a federal derivative complaint that Medtronic paid $40 million to settle complaints of pushing its Infuse product for off-label uses, but kept paying doctors to promote its off-label use, and propped up its share price through false and misleading statements.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.